Key result
BNT162b2 COVID-19 booster linked to rapidly resolving acute perimyocarditis in a 14-year-old male.
Why the study?
Perimyocarditis occurs rarely after COVID-19 vaccination, and no report in Japan had comprehensively described this phenomenon after a booster dose.
Case Report (n=1)
No
This first reported case in Japan demonstrates that a booster dose of the BNT162b2 COVID-19 vaccine can cause acute perimyocarditis in adolescent males, though it follows a benign, self-limiting clinical course.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to possible early perimyocarditis post-BNT162b2 booster in adolescent males; leaves incidence and causality open.
Perimyocarditis is a rare and serious cardiac complication following COVID-19 vaccination. Young males are most at risk after the second dose. With the introduction of the booster (third) dose, some reports have focused on the risk of perimyocarditis after a booster dose. However, no currently available report in Japan has comprehensively described this phenomenon. A healthy 14-year-old Japanese male, who had completed a two-dose primary series of the BNT162b2 (Pfizer-BioNTech) vaccine six months prior, developed fever and chest pain within 24 hours after a homologous booster dose. He was transferred to our institute because of worsening chest pain. A multiplex PCR test showed no evidence of active viral infections, including SARS-CoV-2. Electrocardiography revealed ST-segment elevation in almost all leads, suggesting pericarditis. Echocardiography showed normal systolic function. Laboratory data demonstrated C-reactive protein levels of 8.8 mg/dL and elevated cardiac damage markers (troponin T, 1.9 ng/mL; creatine phosphokinase, 1527 U/L; MB isoenzyme, 120 U/L), suggesting myocarditis. He was diagnosed with perimyocarditis associated with the booster dose, which was confirmed by cardiac magnetic resonance imaging four days after initial symptoms. Chest pain improved spontaneously along with a resolution of electrocardiographic findings and laboratory data within several days. He was discharged eight days after admission. Perimyocarditis is less frequent after a booster dose than after primary doses. In this case, the patient with booster-dose-associated perimyocarditis showed favorable clinical course without severe sequelae. The patient's clinical course was consistent with findings on previous large-scale reports on primary-dose-associated perimyocarditis and case series on booster-dose-associated perimyocarditis.
No takes yet. Share an insight, caveat, or question.
Morita et al. (2022) conducted a case report in Acute perimyocarditis (n=1). BNT162b2 COVID-19 Vaccine was evaluated on Clinical resolution of perimyocarditis. A 14-year-old Japanese male developed acute perimyocarditis within 24 hours after a BNT162b2 COVID-19 booster dose, showing a favorable clinical course with spontaneous resolution within several days.
Synapse has enriched 10 related papers. Consider them for comparative context: